Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239345 | 0.95 | CTSK (0.52) | CTSKCTSS | |
| SCHEMBL5133847 | 0.93 | CTSK (0.51) | CTSKCTSS | |
| SCHEMBL1843190 | 0.89 | CTSK (0.53) | CTSKCTSS | |
| SCHEMBL7804302 | 0.86 | TDP1 (0.50) | CTSKCTSS | |
| SCHEMBL1251053 | 0.84 | TDP1 (0.53) | CTSKCTSS | |
| SCHEMBL28244975 | 0.84 | CTSK (0.59) | CTSKCTSS | |
| SCHEMBL27490793 | 0.83 | MEN1 (0.45) | CTSKCTSS | |
| SCHEMBL5033253 | 0.83 | CYP2D6 (0.49) | CTSKCTSS | |
| SCHEMBL12734596 | 0.82 | CTSK (0.61) | CTSKCTSS | |
| SCHEMBL15961701 | 0.82 | CTSK (0.61) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| WO-2024133845-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | TUBULIS GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| CN-108699558-B | Nucleic acid complexes | 协和麒麟株式会社 | 2021-12-07 | — | — | CN | disclosed |
| CN-113286600-A | Nucleic acid complexes | 协和麒麟株式会社 | 2021-08-20 | — | — | CN | disclosed |
| EP-0986384-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110269943-A1 | RADIOLABELED ANNEXINS | UNIVERSITY OF WASHINGTON (US) | 2011-11-03 | — | — | US | disclosed |
| US-7744853-B2 | Radiolabeled annexins | PONIARD PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7115248-B2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060029545-A1 | Radiolabeled annexins | NEORX CORPORATION, REGENTS OF THE UNIVERSITY OF MICHIGAN | 2006-02-09 | — | — | US | disclosed |
| US-6172045-B1 | COMPLEX CONTAINING 1-DESOXY-1-THIO-N-ACETYLGALACTOSAMINE | NEORX CORPORATION | 2001-01-09 | — | — | US | disclosed |
| WO-2000064904-A1 | 5,7-BICYCLIC AMIDINE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2000-11-02 | — | — | WO | disclosed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000004868-A2 | LIBRARIES OF POLYHYDROXAMATES AND THEIR ANALOGS | METAPHORE, INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| US-5968477-A | IMAGING AGENTS WITH SULFHYDRYL GROUPS AND HEXOSE GROUPS | NEORX CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0918547-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1997046098-A9 | CLUSTER CLEARING AGENTS | — | 1998-08-06 | — | — | WO | disclosed |
| WO-1998004294-A2 | RADIOLABELED ANNEXINS | NEORX CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0229944-A2 | Novel tetrahydroisoquinoline derivatives | SYNTEX (U.S.A.) INC. (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060029545-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CTSK 359/4885CTSS 279/4885 |
| US-20110269943-A1 | RADIOLABELED ANNEXINS | ANXA11, ANXA1, ANXA3 | CTSK 359/4885CTSS 279/4885 |
| US-20240269313-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | PTH1R, SELPLG, CALCR | CTSK 3565/4885CTSS 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.